| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
1,4,7-Triazonane does not have a defined pharmacological target as it is a chelating ligand and biochemical reagent. The compound is an intermediate in the synthesis of 1,4,7-trifunctionalized derivatives that have applications in metal complexation. As a macrocyclic triamine, it serves as a ligand for metal ions in coordination chemistry. Its primary applications are in metal complexation and as a chelating agent.
|
|---|---|
| ln Vitro |
In the process of creating 1,4,7-trifunctionalized derivatives with uses in metal complexation, 1,4,7-triazonane is used as an intermediate[2].
No specific in vitro pharmacological activity data are available for 1,4,7-Triazonane as it is a chelating ligand and biochemical reagent. In research settings, the compound is used as a ligand for metal complexation and as a chelating agent. Its activity is assessed in terms of cation binding selectivity and metal complexation efficiency rather than direct biological activity. |
| ln Vivo |
No specific in vivo pharmacological activity data have been documented for 1,4,7-Triazonane as a therapeutic agent. The compound is used as a chelating ligand and biochemical reagent. It is not administered to animals for pharmacological evaluation. Its applications are limited to coordination chemistry and biochemical research.
|
| Enzyme Assay |
For non-cellular assays, 1,4,7-Triazonane is characterized by standard analytical techniques including NMR, HPLC, and mass spectrometry to confirm identity and purity. Purity is typically ≥95-97%. The compound has a molecular weight of 129.20 and formula C₆H₁₅N₃. Storage: keep in a cool, dry place protected from light and moisture. The compound is a solid at room temperature.
|
| Cell Assay |
For in vitro cell-based studies, 1,4,7-Triazonane is not typically used as a direct test compound. It is used as a chelating ligand and biochemical reagent. If handled in a biological laboratory context, appropriate safety precautions should be taken due to the corrosive nature of the compound. The compound causes severe skin burns and eye damage.
|
| Animal Protocol |
For in vivo animal studies, 1,4,7-Triazonane is not typically administered as a test compound. It is used as a chelating ligand and biochemical reagent. If used in toxicological studies, it would be administered via appropriate routes with suitable formulations. Standard animal welfare guidelines should be followed.
|
| ADME/Pharmacokinetics |
1,4,7-Triazonane has a molecular weight of 129.20 and formula C₆H₁₅N₃. Purity: typically ≥95-97%. Storage: keep in a cool, dry place protected from light and moisture. The compound is a solid at room temperature. Solubility: soluble in water and common organic solvents. The compound is corrosive.
|
| Toxicity/Toxicokinetics |
1,4,7-Triazonane is for research use only and not for human consumption. Standard laboratory safety practices should be followed when handling this chemical. The compound causes severe skin burns and eye damage. Appropriate personal protective equipment including gloves and safety glasses should be worn. Specific LD₅₀ values and detailed toxicological profiles have not been extensively reported.
|
| References |
|
| Additional Infomation |
1,4,7-triazonane is a saturated organic heterocyclic parent compound, a crown amine, and a azacycloalkane.
1,4,7-Triazonane (CAS 4730-54-5) is also known as 1,4,7-triazacyclononane (TACN). It is an intermediate in the synthesis of 1,4,7-trifunctionalized derivatives for metal complexation. It is a complex titration reagent with high cation binding selectivity. No clinical trials or therapeutic approvals exist. |
| Molecular Formula |
C6H15N3
|
|---|---|
| Molecular Weight |
129.20
|
| Exact Mass |
129.126
|
| CAS # |
4730-54-5
|
| PubChem CID |
188318
|
| Appearance |
White to yellow solid powder
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
254.1±0.0 °C at 760 mmHg
|
| Melting Point |
42-45ºC(lit.)
|
| Flash Point |
87.2±13.5 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.424
|
| LogP |
-1.76
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
9
|
| Complexity |
45.1
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CNCCNCCN1
|
| InChi Key |
ITWBWJFEJCHKSN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H15N3/c1-2-8-5-6-9-4-3-7-1/h7-9H,1-6H2
|
| Chemical Name |
1,4,7-triazonane
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~774.0 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (19.35 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (19.35 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (19.35 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.7399 mL | 38.6997 mL | 77.3994 mL | |
| 5 mM | 1.5480 mL | 7.7399 mL | 15.4799 mL | |
| 10 mM | 0.7740 mL | 3.8700 mL | 7.7399 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
